6 patients with definite MS underwent lymphocytoplasmapheresis for one year. Clinical data, evoked potential recordings and peripheral blood lymphocyte helper/suppressor ratio were assessed before and after the treatment and were compared with those of a control group of 10 multiple sclerosis patients. Lymphocytoplasmapheresis did not significantly modify clinical and laboratory findings compared with the control group.